Evidence map›Paper›PMID 36865304›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Excess burden of respiratory and abdominal conditions following COVID-19 infections during the ancestral and Delta variant periods in the United States: An EHR-based cohort study from the RECOVER Program.

Jay K Varma, Chengxi Zang, Thomas W Carton, Jason P Block, Dhruv J Khullar, Yongkang Zhang, Mark G Weiner, Russell L Rothman, Edward J Schenck, Zhenxing Xu and 9 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Jay K VarmaDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Chengxi ZangDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Thomas W CartonLouisiana Public Health Institute, New Orleans, LA.
Jason P BlockDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, MA.
Dhruv J KhullarDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Yongkang ZhangDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Mark G WeinerDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Russell L RothmanInstitute for Medicine and Public Health, Vanderbilt University Medical Center Nashville, TN.
Edward J SchenckDepartment of Medicine, Weill Cornell Medicine, New York, NY.
Zhenxing XuDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Kristin LymanDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Jiang BianHealth Outcomes and Biomedical Informatics, University of Florida Health, Gainesville, FL.
Jie XuHealth Outcomes and Biomedical Informatics, University of Florida Health, Gainesville, FL.
Elizabeth A ShenkmanHealth Outcomes and Biomedical Informatics, University of Florida Health, Gainesville, FL.
Christine MaughanUtah COVID-19 Long Haulers.
Leah Castro-BaucomPatient representative.
Lisa O'BrienUtah COVID-19 Long Haulers.
Fei WangDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Rainu KaushalDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Cornell University · USUniversity of Florida Health · USHarvard University · USLouisiana Public Health Institute · USVanderbilt University Medical Center · US

Funding

OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository CoreOT2HL161847 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GROSS, RACHEL SHARON, HORWITZ, LEORA · 2021 to 2025
$651.0M
NHLBI NIH HHS OT2 HL161847
6 · The paper itself

Abstract

Importance: The frequency and characteristics of post-acute sequelae of SARS-CoV-2 infection (PASC) may vary by SARS-CoV-2 variant. Objective: To characterize PASC-related conditions among individuals likely infected by the ancestral strain in 2020 and individuals likely infected by the Delta variant in 2021. Design: Retrospective cohort study of electronic medical record data for approximately 27 million patients from March 1, 2020-November 30, 2021. Setting: Healthcare facilities in New York and Florida. Participants: Patients who were at least 20 years old and had diagnosis codes that included at least one SARS-CoV-2 viral test during the study period. Exposure: Laboratory-confirmed COVID-19 infection, classified by the most common variant prevalent in those regions at the time. Main Outcomes and Measures: Relative risk (estimated by adjusted hazard ratio [aHR]) and absolute risk difference (estimated by adjusted excess burden) of new conditions, defined as new documentation of symptoms or diagnoses, in persons between 31-180 days after a positive COVID-19 test compared to persons with only negative tests during the 31-180 days after the last negative test. Results: We analyzed data from 560,752 patients. The median age was 57 years; 60.3% were female, 20.0% non-Hispanic Black, and 19.6% Hispanic. During the study period, 57,616 patients had a positive SARS-CoV-2 test; 503,136 did not. For infections during the ancestral strain period, pulmonary fibrosis, edema (excess fluid), and inflammation had the largest aHR, comparing those with a positive test to those with a negative test, (aHR 2.32 [95% CI 2.09 2.57]), and dyspnea (shortness of breath) carried the largest excess burden (47.6 more cases per 1,000 persons). For infections during the Delta period, pulmonary embolism had the largest aHR comparing those with a positive test to a negative test (aHR 2.18 [95% CI 1.57, 3.01]), and abdominal pain carried the largest excess burden (85.3 more cases per 1,000 persons). Conclusions and Relevance: We documented a substantial relative risk of pulmonary embolism and large absolute risk difference of abdomen-related symptoms after SARS-CoV-2 infection during the Delta variant period. As new SARS-CoV-2 variants emerge, researchers and clinicians should monitor patients for changing symptoms and conditions that develop after infection.

Identifiers

PMID36865304
PMCPMC9980238
OpenAlexW4321606364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.